MaRVis Technologies GMBH
This article was originally published in Start Up
Executive Summary
Physicians continue to wait patiently for the day they can perform interventional cardiovascular and neurological procedures using magnetic resonance imaging (MRI) for guidance instead of x-ray. However, current guidewires and catheters don't work because they contain metal components that can distort MR imaging or potentially heat up inside the patient. To the rescue: MaRVis Technologies, which is developing guidewires and catheters that lack a metal core. The company's devices are built in a multi-composite manner--from core rods composed of fiberglass filaments enclosed with epoxy resin and doped with small metal particles--for MRI compatibility and visualization and to maintain the desirable material characteristics of current guidewires and catheters.
You may also be interested in...
Start-Up Previews (02/2009)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Building the Next-Generation of GPCR-Targeting Drugs," features profiles of Catena Pharmaceuticals, Dimerix Bioscience, Heptares Therapeutics and Trevena. Plus these Start-Ups Across Health Care: Carmat, Glycan Biosciences, Itero and MaRVis Technologies.
Start-Up Previews (02/2009)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Building the Next-Generation of GPCR-Targeting Drugs," features profiles of Catena Pharmaceuticals, Dimerix Bioscience, Heptares Therapeutics and Trevena. Plus these Start-Ups Across Health Care: Carmat, Glycan Biosciences, Itero and MaRVis Technologies.
In Rapidly-Growing MRI Field, Where's the Opportunity for Start-Ups?
Among imaging modalities used to guide surgery, magnetic resonance imaging (MRI) is growing at the fastest rate. According to “"US Markets for Imaged-Guided Surgery Products,"” published in November 2007 by Medtech Insight, MRI systems used in surgery or interventional procedures accounted for 12.5% of the $1.24 billion in surgical interventional imaging sales in the US in 2006, and procedure volumes are expected to grow at a compound annual rate of 9.2% through the year 2011. While it's obvious that the diagnostic imaging giants are positioned to enjoy the growth in emerging applications of MRI, start-ups can profit too.